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All patients reported confidence
with the advice given and completeness
of information received, and felt their
concerns were addressed. Individuals in
both groups sought other opinions, most
commonly from their family practitio-
ner. Those that declined adjuvant ther-
apy frequently commented on perceived
support from healthcare professionals
and family, suggesting that lack of sup-
port during decision-making was not a
barrier to accepting treatment. It might
also suggest that those who choose op-
tions other than the oncologists’ recom-
mendation feel a greater need to justify
their decision. Finally, despite available
data from randomized trials, few pa-
tients in either group recalled being pro-
vided with survival statistics from clin-
ical trials during their decision-making
process, but most were satisfied with the
process.
Based on our initial findings, it
seems that patients who decline adju-
vant therapy tend to access fewer infor-
mation resources in the decision-making
process, and focus on the potential for
severe toxicity and negative outcomes.
Thus, better education strategies should
be considered for some patients, and
information and decision support should
be tailored to meet the needs and values
of the individual. A number of decision
aids are under development for this
group, and may improve decision-mak-
ing regarding adjuvant therapy for lung
cancer.
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Immune Hemolytic
Anemia After
Treatment with
Pemetrexed for Lung
Cancer
To the Editor:
Pemetrexed is a structurally novel
antifolate agent. Unlike the “classic” an-
timetabolite drugs including methotrex-
ate and fluorouracil which target a single
enzyme, pemetrexate and its polygluta-
mated forms inhibit enzymes that re-
quire folate, such as dihydrofolate re-
ductase, thymidylate synthase, and
glycinamide ribonucleotide formyl-
transferase.1 The United States Food
and Drug Administration has approved
pemetrexed in combination with cispla-
tin for the treatment of patients with
malignant pleural mesothelioma. Pem-
etrexed has also been approved for use
as a single agent for previously treated
patients with locally advanced or meta-
static non-small cell lung cancer on
2004.2 Although several drug-related
deaths with severe hematologic toxicity
were seen in the early trials of pem-
etrexed, they were overcome by supple-
mentation of folate and vitamin B12. In
the phase III trials that led to the drug’s
approval, immune hemolytic anemia
(IHA) was never reported in patients
receiving pemetrexed alone or in com-
bination with cisplatin.
A 62-year-old man was admitted
for evaluation of a newly developed
neck mass. The chest computed tomog-
raphy scan showed 6-cm-sized lung
mass in the right upper lobe and meta-
static nodules in the left lower lobe.
Adenocarcinoma was diagnosed by
means of excisional biopsy of the neck
mass. Despite several chemotherapy tri-
als using different regimens such as pac-
litaxel plus cisplatin and gefitinib, the
patient’s lung cancer continuously pro-
gressed. As a final salvage chemother-
apy regimen, pemetrexed was given to-
gether with vitamin supplementation.
The baseline hemoglobin, lactate dehy-
drogenase, and total bilirubin were 97
g/l (130–170 g/l), 451 IU/l (240–480
IU/l), and 0.2 mg/dl (0.2–1.3 mg/dl),
respectively. After 20 days, the hemo-
globin level suddenly dropped to 43 g/l
without any evidence of bleeding on
endoscopy, stool occult blood test, and
urine analysis. The white blood cell
count and platelet count were normal.
There were no deficiencies of iron, fo-
late, and vitamin B12. The serum lactate
dehydrogenase was elevated to 711 IU/l
and the total bilirubin was 1.8 mg/dl
without a detectable level of conjugated
form. The reticulocyte production index
was increased to 2.74. Anistocytosis,
poikilocytosis, and polychromasia with
numerous nucleated red blood cells
(RBCs) were found on peripheral blood
smear, suggesting hemolytic anemia
(Figure 1). The results of direct anti-
globulin test performed by tube and gel
microcolumn assay were positive with
only anti-C3d (1). In the drug in vitro
tests, agglutination was observed at
37°C (1) only when the patient’s se-
rum sample was mixed with enzyme-
treated red cells in the presence of pem-
etrexed. Taken together, we detected an
antibody to pemetrexed which appeared to
be the likely cause of the patient’s IHA.
As for treatment, transfusion of packed
RBCs was done together with indefinite
cessation of pemetrexed. The patient’s he-
moglobin level normalized and was sus-
tained without any steroid therapy.
Many drugs, including chemothera-
peutic agents, are known to cause drug-
induced IHA. Methotrexate, a dihydrofo-
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late reductase inhibitor, and pyrimidine
analogs such as fluorouracil and tegafur
and uracil have all been reported to
cause IHA.3–5 In drug-induced IHA,
drug-induced antibodies can be divided
into two types. One is drug-independent
antibody (autoantibody type), which
does not require the presence of the drug
for their detection, and the other is drug-
dependent antibody that requires the
presence of the drug for their detection.
There are two subtypes in drug-depen-
dent antibodies. The first is the antibody
that reacts with drug-coated RBCs and is
inhibited by the addition of soluble drug
(drug adsorption type), and the second is
the antibody that does not react with drug-
treated RBCs but only reacts when the
drug, antibody, and RBCs are mixed (neo-
antigen type). In this case, the patient’s
RBCs were coated with C3d, but not IgG.
The immune complex test was positive in
the presence of pemetrexed. Thus, anti-
pemetrexed antibody may have been the
cause of the patient’s auto-IHA. In the
treatment of IHA, if the hemolysis is clin-
ically significant, the suspected drug
should be discontinued. Corticosteroids
may aid the recovery in severe cases, and
RBC transfusions can also be done.
To the best of our knowledge, this
is the first reported case of severe warm
auto-IHA associated with pemetrexed.
Based on our experience, patients re-
ceiving pemetrexed for non-small cell
lung cancer should be carefully moni-
tored for drops in hemoglobin level and
their physicians should keep in mind the
possibility of IHA because of pem-
etrexed.
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FIGURE 1. Peripheral blood smear of this patient shows the typical findings of
immune hemolytic anemia, which are spherocytes (black arrow), polychromato-
philic red cells (white arrow), and nucleated red blood cells (arrowhead) (1,000,
Wright stain).
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